Associate Professor MAYO CLINIC ROCHESTER Rochester, Minnesota, United States
This session explores the genetic basis of individual variability in response to topiramate, a widely used preventive medication for migraine. Using whole genome sequencing (WGS) and genome-wide association studies (GWAS), we identified genetic variants and pathways—such as GABAergic signaling—potentially influencing treatment outcomes. Attendees will gain insights into how pharmacogenomics can guide personalized migraine therapy, the design and analysis of WGS/GWAS data, and the importance of integrating genetic findings with biological mechanisms. This work highlights the potential of precision medicine approaches in improving migraine management.
Learning Objectives:
Understand the need for preventive migraine treatment and variability in topiramate response
Recognize the role of pharmacogenomics in identifying genetic factors influencing treatment outcomes
Describe how whole genome sequencing and genome-wide association studies are used to discover variants linked to topiramate response
